• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Home » Archives for Jon C. Mirsalis
Jon C. Mirsalis

Jon C. Mirsalis

VP Translational Development
Go to bio page

Publications

Biomedical sciences publications February 8, 2022

Enhancement of sensitivity and quantification quality in the LC-MS/MS measurement of large biomolecules with sum of MRM (SMRM)

Carol Green, Jon C. Mirsalis

We describe here an approach to boost detection sensitivity and expand dynamic range in the quantitation of large molecules while maintaining analytical specificity using summation of MRM (SMRM) transitions and LC separation technique.

Biomedical sciences publications October 20, 2020

Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys

Jon C. Mirsalis

In this study, we have used filter-aided sample preparation (FASP) and tandem mass tag (TMT) labeling to investigate serum protein alterations in isoproterenol-treated African green monkeys.

Biomedical sciences publications December 27, 2019

In Vivo Activity of Amodiaquine against Ebola Virus Infection

Jon C. Mirsalis

We investigated the potential anti-EBOV effect of amodiaquine in a well-characterized nonhuman primate model of EVD.

Biomedical sciences publications May 21, 2019

Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats

Jon C. Mirsalis

The generalized stress inherent to head-out plethysmography testing exacerbated the respiratory effects of DSM421 and was possibly compounded by DSM421’s cardiovascular effects, thus artifactually resulting in moribundity and mortality in rats.

Biomedical sciences publications November 3, 2015 Article

Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy

Jon C. Mirsalis

Clinically relevant linezolid regimens were simulated in the in vitro hollow-fiber infection model (HFIM) system to identify the linezolid therapies that minimize toxicity, maximize antibacterial activity, and prevent drug resistance.

Biomedical sciences publications March 1, 2015 Article

Preclinical Studies on the Pharmacokinetics, Safety, and Toxicology of Oxfendazole: Toward First in Human Studies

Jon C. Mirsalis

A 2-week study in rats identified target organs of oxfendazole toxicity to be bone marrow, epididymis, liver, spleen, testis, and thymus. Female rats had greater oxfendazole exposure and exhibited toxicities at lower doses than did males. Decreased white blood cell levels, a class effect of benzimidazole anthelmintics, returned to normal during the recovery period. The no observed adverse effect level was determined to be >5 but <25 mg/kg/d and the maximum tolerated dose 100 mg/kg/d. The highest dose, 200 mg/kg/d, resulted in significant toxicity and mortality, leading to euthanization of the main study animals in this group after 7 days. Oxfendazole did not exhibit genetic toxicology signals in standard Ames bacterial, mouse lymphoma, or rat micronucleus assays nor did it provoke safety concerns when evaluated for behavioral effects in rats or cardiovascular safety effects in dogs. These results support the transition of oxfendazole to First in Human safety studies preliminary to its evaluation in human helminth diseases

Biomedical sciences publications January 1, 2015

Tenofovir Disoproxil Fumarate: Toxicity, Toxicokinetics, and Toxicogenomics Analysis After 13 Weeks of Oral Administration in Mice

Jon C. Mirsalis, Denong Wang

The goals of this study were to evaluate the molecular mechanism of TDF-induced toxicity in mice by correlating transcriptional changes with plasma drug levels and traditional toxicology end points.

Biomedical sciences publications June 1, 2013

Non-Clinical Safety Evaluation of Xoma 3AB, a Novel Triple Antibody Drug Product Targeting Botulinum Toxin Type a, in Sprague-Dawley Rats

Carol Green, Jon C. Mirsalis

SRI menlo-building-walkway-abstract placeholder banner
Blog archive September 13, 2012

The Role of Nonprofit Institutes in Pharmaceutical Development

Jon C. Mirsalis

When I describe to friends and colleagues what I do for a living, I typically get a response like, “So, you are really no different than a pharmaceutical company.” Exactly. And not at all. SRI International has played a major role in the development of therapeutics for a wide range of diseases over the years […]

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International